

Product Data Sheet

BMS-833923

Cat. No.:	A3258
CAS No.:	1059734-66-5
Formula:	C30H27N5O
M.Wt:	473.57
Synonyms:	BMS 833923;BMS833923;XL-139;XL139;XL 139
Target:	Stem Cell
Pathway:	Smoothened
Storage:	Store at -20°C



Solvent & Solubility

≥47.4 mg/mL in DMSO; insoluble in H₂O; ≥5.14 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1mg	5mg	10mg
	1 mM		2.1116 mL	10.5581 mL	21.1162 mL
	5 mM		0.4223 mL	2.1116 mL	4.2232 mL
	10 mM		0.2112 mL	1.0558 mL	2.1116 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Smoothened inhibitor

IC₅₀ & Target

6-35 nM (Smoothened)

Cell Viability Assay

In Vitro

Cell Line:	OE19 (JROECL19) and OE33 (JROECL33) esophageal adenocarcinoma(EAC) cell lines
Preparation method:	The solubility of this compound in DMSO is >47.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored

		below -20°C for several months.
	Reacting conditions:	0 to 100 µM for 24 and 48 hr
	Applications:	In OE19 and OE33 cells, BMS-833923 (10 µM) inhibited cell proliferation with the IC50 of 10 µM. BMS-833923 (25 µM) completely inhibited cell proliferation. In OE19 and OE33 cells, treatment with 10 µM BMS-833923 resulted in 82 and 73.4% apoptotic cells, respectively.
In Vivo	Animal experiment	
	Animal models:	Medulloblastoma and pancreatic carcinoma xenografts mouse models, Male Sprague-Dawley rats with gastroesophageal reflux disease
	Dosage form:	Oral administration, 10 mg/kg
	Applications:	In medulloblastoma and pancreatic carcinoma xenografts animal models, administration of BMS-833923 at single oral dose showed robust inhibition of Hh pathway. In a rat model with gastroesophageal reflux disease, administration of BMS-833923 (10 mg/kg/day) resulted in the decreased development of both Barrett esophagus and esophageal adenocarcinoma by 35.7%.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Zaidi A H, Komatsu Y, Kelly L A, et al. Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. Cancer investigation, 2013, 31(7): 480-489.
- [2]. Gendreau S B, Hawkins D, Ho C P, et al. Abstract B192: Preclinical characterization of BMS - 833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics, 2009, 8(12 Supplement): B192-B192.
- [3]. Gibson M K, Zaidi A H, Davison J M, et al. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Annals of surgery, 2013, 258(1): 82-88.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.



Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

